Status: Recruiting
Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
The primary objective of this study is to assess the platelet count response to ravulizumab in participants clinically diagnosed as atypical hemolytic uremic syndrome (aHUS).
Participants needed: 20
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Alexion Pharmaceuticals, Inc.Updated: Apr 20, 2026Locations: 12
Eligibility criteria
Body weight ≥20 kilograms (kg) [+13]
Participants with TTP, STEC-HUS, secondary TMA that is obviously unrelated to co... [+7]